1. Please check and comment entries here.
Table of Contents

    Topic review

    Neural Stem Cell-Based Therapy

    Subjects: Cell Biology | Biology
    View times: 16
    Submitted by: Farah Amna Othman
    (This entry belongs to Entry Collection "Neuronal Degeneration ")

    Definition

    Transplantation of neural stem cells (NSCs) has been proposed as an alternative novel therapy to replace damaged neural circuitry after ischemic stroke onset. Nonetheless, albeit the potential of these cells for stroke therapy, many critical challenges are yet to be overcome to reach clinical applications. The major limitation of the NSC-based therapy is its inability to retain most of the donor stem cells after grafting into an ischemic brain area which is lacking of essential oxygen and nutrients for the survival of transplanted cells. Low cell survival rate limits the capacity of NSCs to repair the injured area and this poses a much more difficult challenge to the NSC-based therapy for ischemic stroke. In order to enhance the survival of transplanted cells, several stem cell culture preconditioning strategies have been employed. For ischemic diseases, hypoxic preconditioning is the most commonly applied strategy since the last few decades. Now, the preconditioning strategies have been developed and expanded enormously throughout years of efforts. This entry systematically presented studies searched from PubMed, ScienceDirect, Web of Science, Scopus and the Google Scholar database up to 31 March 2020 based on search words containing the following terms:“precondition” or “pretreatment” and “neural stem cell” and “ischemic stroke”. The searched data comprehensively reported seven major NSC preconditioning strategies including hypoxic condition, small drug molecules such as minocycline, doxycycline, interleukin-6, adjudin, sodium butyrate and nicorandil, as well as electrical stimulation using conductive polymer for ischemic stroke treatment. We discussed therapeutic benefits gained from these preconditioned NSC for in vitro and in vivo stroke studies and the detailed insights of the mechanisms underlying these preconditioning approaches. Nonetheless, there was a scarcity of evidence on the ecacy of these preconditioned NSCs in human clinical studies, therefore, it is still too early to draw a definitive conclusion on the efficacy and safety of this active compound for patient usage. Thus, we suggest for more in-depth clinical investigations of this cell-based therapy to develop into more conscientious and judicious evidence-based therapy for clinical application in the future.

    1. Introduction

    Stroke is defined as rapid neurological dysfunction due to the disturbance in cerebral blood supply, with acute onset of clinical signs and symptoms persisting for more than 24 h or until death. It is a leading cause of neuronal impairment and adult disability worldwide in which about 70% of the stroke survivors suffer from reduced work capacity, while the remaining 30% require self-management assistance. About 85% of the stroke cases reported are classified as ischemic stroke, a focal neurological deficit that occurs due to insufficient cerebral blood flow (CBF) triggered by occlusion of blood vessel [1]. CBF less than 20 mL/100 g of brain tissue per minute will lead to irreversible neuronal injury within an hour, whilst a complete absence of CBF within 4–10 min will cause immediate death of brain tissue [2]. The onset of ischemic neuronal injury is initiated by the disruption of brain nutrient, energy and oxygen, which elicits a series of interrelated and coordinated biochemical events that eventually lead to the neurovascular unit damage within the core of infarction. These biochemical events include ionic imperturbation, release of excess glutamate which leads to excitotoxicity, rapid increase in intracellular calcium that in turn activates multiple intracellular death pathways, accumulation of pro-inflammatory cytokines which promotes inflammatory injury and ultimately production of free radicals which leads to irreversible damage of the respiratory chain, mitochondrial dysfunction and eventually neuronal cell death [3].

    The neuronal cell death that occurs following ischemic stroke can be reduced if the blood flow occlusion is removed and tissue reperfusion is restored quickly. Treatment for patients with acute ischemic stroke is guided by the time from the onset of stroke, the severity of neurologic deficit and findings on neuroimaging. It was proved that intravenous thrombolysis with intravenous recombinant tissue plasminogen activator (rtPA, alteplase) administration significantly reduced mortality and disability associated with ischemic stroke within 4.5 h after onset [4][5]. Later treatment may improve outcomes in selected patients, with the treatment window extended to 9 h from onset. Moreover, there is growing evidence that intra-arterial catheter-based mechanical thrombectomy of occluded large intracranial arteries improves outcomes in selected patients with acute ischemic stroke when performed up to 24 h after onset [6]. Nonetheless, despite the fact that these primary therapies could allow rapid restoration of blood supply and reduce stroke-related disability and mortality, they are unable to trigger regeneration of new viable neuronal cells to replace the damaged brain tissue and thus cannot completely restore the brain function [7]. As a consequence, poor prognosis is observed among ischemic stroke patients. This is indicated by the reports which showed that almost one-third of stroke patients who received the clinical stroke treatment are unable to ambulate even after treatment [8], and almost half of stroke patients who have suffered a first stroke are at risk of recurrent stroke within a few days or weeks after the initial treatment [9]. The constraints of current ischemic stroke therapy have led to the demand for alternative therapeutic approaches such as using robust neural stem cell (NSC)-based therapy to promote brain repair and remodeling in stroke-induced injury patients [10].

    2. Neural Stem Cell (NSC) Treatment for Ischemic Stroke

    Survival, proliferation, migration and differentiation of NSC are the key regenerative processes to promote post ischemic recovery. Reports had shown that patients with ischemic stroke injury are capable of undergoing natural endogenous neurogenesis at the ischemic penumbra region of the brain [11][12][13]. Endogenous NSCs reside in two active neurogenesis brain regions: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus [14] (Figure 1). Under normal physiological conditions, these endogenous NSCs remain quiescent in adult brains. After ischemic injury, the endogenous NSCs are activated to proliferate and migrate towards the lesion site by several neurotrophic factors secreted by the ischemic brain tissue. The factors include brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), cytokines like monocyte chemoattractant protein (MCP-1) and macrophage inflammatory protein (MIP-1) [14]. Within a week after the lesion, newly generated neurons appear at the boundary of the damaged area [15], implying that neuroregenerative therapy using endogenous NSCs is highly anticipated as an effective strategy for treating degenerative brain diseases such as ischemic stroke. Nonetheless, this spontaneous regeneration by endogenous NSCs is insufficient for structural or functional restoration of the injured brain, as the majority of these newly formed neurons die before functional maturation, leaving only a limited number of cells which could stably integrate into the neuronal circuitry [16].

    Figure 1. The sagittal brain section illustrated the location of the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (DG) regions.

    Therefore, current NSC-based therapy not only depends on endogenous repair, but also depends on exogenous NSC transplantation from independent sources. The exogenous NSC transplantation approach exhibits therapeutic potential since it is not only capable of directly replacing the damaged brain tissue, but also able to secrete neuroprotective factors to protect brain tissue at risk during the acute phase of the stroke. Reports of exogenous NSC transplantation in ischemic stroke-induced animal models showed promising data, with conclusive efficacy and potential of this therapy. Majority of the studies reported improved prognosis of this disease after exogenous NSC transplantation such as improved neurological functions and strengthened motor skills [17]. Basically, the exogenous NSC transplantation focuses on two strategies: replace dead cells in the infarcted area or enhance the self-repair system by providing trophic support to mediate the neural network reconstruction [18]. Furthermore, the exogenous NSCs could be preconditioned prior to transplantation to enhance its therapeutic potential for ischemic stroke. Preconditioning strategies have been tested in many types of stem cells, including NSCs, to increase grafted cell survival rate and their therapeutic potential within hostile ischemic brain microenvironments. The concept of preconditioning was first described in the past 30 years. It applied the hormesis biological concept, whereby one or more brief episodes of sub-lethal stimuli was introduced to render the endogenous protective mechanisms against subsequent lethal injury [19]. In recent years, various preconditioning strategies have been developed and explored to improve donor cell survival after transplantation. Nonetheless, there is still no systematic review to report and vindicate the potential of these preconditioning strategies for exogenous NSC transplantation-based therapy.

    3. Recommendations and Future Perspective of Preconditioned-NSC Therapy

    Despite the fact that limited clinical data is available to date, NSCs preconditioned by hypoxic condition, small molecules such as minocycline, doxycycline, adjudin, IL-6, combination of NaB and nicorandil, as well as electrical stimulation had been found to significantly improve cell survival and biological functions of transplanted cells in experimental scenarios. From the largely flourishing outcomes in the experimental models, preconditioned NSC definitely possesses potential to be applied in clinical treatments, provided all the issues and impracticalities are effectively addressed and solved in future.

    Besides, we noticed that the preconditioning methods discussed in this article involved NSCs isolated from different resources, for example, NSCs derived from hemispheres hippocampus of fetal rat brains (hypoxic preconditioning) [20], NSCs harvested from SVZ of fetal rat brains (minocycline [21] and doxycline [22] preconditioning), NSCs harvested from SVZ of fetal mice brains (IL-6 preconditioning) [23], NSCs harvested from bilateral cortex of mouse brains (adjudin preconditioning) [24], NSCs harvested from mouse 14-day-old embryo ganglion eminence (combined NaB and nicorandil preconditioning) [25], and human neural progenitor cells (hNPCs) derived from H9 human embryonic stem cell line (electrical preconditioning) [26]. Each of these NSC types has a different origin and its own unique characteristics. Therefore, further investigations are required to determine the effectiveness and consistency of these preconditioning strategies on different NSC types, as well as the optimum timing of the treatment. This research gap could be further explored in future by researchers in related field.

    Another important aspect that needs to be considered for preconditioned NSCs-based therapy is its long term safety, particularly with regard to the potential of tumorigenicity after stimulation by preconditioning approaches. In order to further enhance the efficacy of stem cell-based transplantation therapy, a combination of NSC engineering strategies with preconditioning strategies is recommended to provide enhanced cell replacement, trophic support, immunomodulatory as well as regenerative potential for better therapeutic effects. In addition, alternative treatments using NSC-derived extracellular vesicles (EV) have also been highlighted recently in neurodegenerative disease. This EV-based therapy has spurred a renewed interest in their utility for a cell-free therapeutics option, where it could avoid problems encountered by NSCs-based therapy such as low cell survival rate and high graft rejection after transplantation.

    The entry is from 10.3390/brainsci10110893

    References

    1. Katan, M.; Luft, A. Global Burden of Stroke. Semin. Neurol. 2018, 38, 208–211.
    2. Smith, W.S.; Johnston, S.; Easton, J.D. Cerebrovascular Diseases. Harrison’s Principles of Internal Medicine, 16th ed.; McGraw-Hill Medical Publishing Division: New York, NY, USA, 2005.
    3. Aggarwal, A.; Aggarwal, P.; Khatak, M.; Khatak, S. Cerebral ischemic stroke: Sequels of cascade. Int. J. Pharma Bio Sci. 2010, 1, 1–24.
    4. Liu, S.; Feng, X.; Jin, R.; Li, G. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. Expert Opin. Drug Deliv. 2018, 15, 173–184.
    5. Lansberg, M.G.; Bluhmki, E.; Thijs, V.N. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: A metaanalysis. Stroke 2009, 40, 2438–2441.
    6. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418.
    7. Khandelwal, P.; Yavagal, D.R.; Sacco, R.L. Acute Ischemic Stroke Intervention. J. Am. Coll. Cardiol. 2016, 67, 2631–2644.
    8. Leng, T.; Xiong, Z.-G. Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges. Brain Circ. 2019, 5, 8–11.
    9. Arsava, E.M.; Kim, G.-M.; Oliveira-Filho, J.; Gungor, L.; Noh, H.J.; de Jesus Lordelo, M.; Avery, R.; Maier, I.L.; Ay, H. Prediction of Early Recurrence after Acute Ischemic Stroke. JAMA Neurol. 2016, 73, 396.
    10. Kwak, K.-A.; Kwon, H.-B.; Lee, J.W.; Park, Y.-S. Current Perspectives Regarding Stem Cell-based Therapy for Ischemic Stroke. Curr. Pharm. Des. 2018, 24, 3332–3340.
    11. Macas, J.; Nern, C.; Plate, K.H.; Momma, S. Increased generation of neuronal progenitors after ischemic injury in the aged adult human forebrain. J. Neurosci. 2006, 26, 13114–13119.
    12. Jin, K.; Wang, X.; Xie, L.; Mao, X.O.; Zhu, W.; Wang, Y.; Shen, J.; Mao, Y.; Banwait, S.; Greenberg, D.A. Evidence for stroke-induced neurogenesis in the human brain. Proc. Natl. Acad. Sci. USA 2006, 103, 13198–13202.
    13. Martí-Fàbregas, J.; Romaguera-Ros, M.; Gómez-Pinedo, U.; Martínez-Ramírez, S.; Jiménez-Xarrié, E.; Marín, R.; Martí-Vilalta, J.L.; García-Verdugo, J.M. Proliferation in the human ipsilateral subventricular zone after ischemic stroke. Neurology 2010, 74, 357–365.
    14. Ming, G.-L.; Song, H.; Questions, S. Adult neurogenesis in the mammalien brain: Significant answers and significant questions. Neuron 2012, 70, 687–702.
    15. Reis, C.; Wilkinson, M.; Reis, H.; Akyol, O.; Gospodarev, V.; Araujo, C.; Chen, S.; Zhang, J.H. A look into stem cell therapy: Exploring the options for treatment of ischemic stroke. Stem Cells Int. 2017, 2017, 3267352.
    16. Arvidsson, A.; Collin, T.; Kirik, D.; Kokaia, Z.; Lindvall, O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 2002, 8, 963–970.
    17. Banerjee, S.; Williamson, D.; Habib, N.; Gordon, M.; Chataway, J. Human stem cell therapy in ischaemic stroke: A review. Age Ageing 2010, 40, 7–13.
    18. Zhang, G.-L.; Zhu, Z.-H.; Wang, Y.-Z. Neural stem cell transplantation therapy for brain ischemic stroke: Review and perspectives. World J. Stem Cells 2019, 11, 817–830.
    19. Sart, S.; Ma, T.; Li, Y. Preconditioning stem cells for in vivo delivery. Biores. Open Access 2014, 3, 137–149.
    20. Wang, Q.; Yang, L.; Wang, Y. Enhanced Differentiation of Neural Stem Cells to Neurons and Promotion of Neurite Outgrowth by Oxygen-Glucose Deprivation. Int. J. Dev. Neurosci. 2015, 43, 50–57.
    21. Sakata, H.; Niizuma, K.; Yoshioka, H.; Kim, G.S.; Jung, J.E.; Katsu, M.; Narasimhan, P.; Maier, C.M.; Nishiyama, Y.; Chan, P.H. Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats. J. Neurosci. 2012, 32, 3462–3473.
    22. Malik, Y.S.; Sheikh, M.A.; Zhu, X. Doxycycline Can Stimulate Cytoprotection in Neural Stem Cells with Oxygen-Glucose Deprivation-Reoxygenation Injury: A Potential Approach to Enhance Effectiveness of Cell Transplantation Therapy. Biochem. Biophys. Res. Commun. 2013, 432, 355–358.
    23. Sakata, H.; Narasimhan, P.; Niizuma, K.; Maier, C.M.; Wakai, T.; Chan, P.H. Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice. Brain 2012, 135, 3298–3310.
    24. Zhang, T.; Yang, X.; Liu, T.; Shao, J.; Fu, N.; Yan, A.; Geng, K.; Xia, W. Adjudin-Preconditioned Neural Stem Cells Enhance Neuroprotection after Ischemia Reperfusion in Mice. Stem Cell Res. Ther. 2017, 8, 248.
    25. Hosseini, S.M.; Ziaee, S.M.; Haider, K.H.; Karimi, A.; Tabeshmehr, P.; Abbasi, Z. Preconditioned Neurons with NaB and Nicorandil, a Favorable Source for Stroke Cell Therapy. J. Cell. Biochem. 2018, 119, 10301–10313.
    26. George, P.M.; Bliss, T.M.; Hua, T.; Lee, A.; Oh, B.; Levinson, A.; Mehta, S.; Sun, G.; Steinberg, G.K. Electrical preconditioning of stem cells with a conductive polymer scaffold enhances stroke recovery. Biomaterials 2017, 142, 31–40.
    More